Q3 Medical GROUP

CREATING VALUE BY HELPING PEOPLE



AWARENESS MONTH
PANCREATIC CANCER
NOVEMBER

SCAN THE QR CODE TO WATCH WORLD LEADING CLINICIANS TALK ABOUT Q3'S BIODEGRADABLE TECHNOLOGY

Dear All,

It is Pancreatic Cancer awareness month, and it is likely that many of you like myself have had a family member or friend that has been impacted by this lethal disease. Pancreatic cancer is the 12th most common cancer worldwide and is a disease that effects every 4.9 per 100,000 people. The 5-year survival rate associated with this disease is in the single digits and the disease is mostly seen in the elderly.

Pancreatic cancer is one of the leading causes of cancer deaths globally with a very low long term survival rate. Most patients present with an advanced stage of the disease with 30-40% being unresectable.

It is true that there are many factors that impact the outcome when a surgical procedure is chosen as the course of treatment such as:

- **Hospital setting**
- **Socioeconomic level of the patients**
- **The expertise of the surgeons and staff**
- **The shear stress of the procedure**

History

Allen Whipple described pancreaticoduodenectomy in the year 1935 when he modified the procedure that was performed before by Alessandro Codivilla in Italy and Walter Keusch in Germany. Although the treatment has been widely used for numerous years and the technique has significantly improved with modification to the surgical approach and the advent of laparoscopic and robotic assisted techniques, complications in these procedures happen routinely and impact the outcome for patients. These complications include delayed gastric emptying and gastrointestinal leaks which impact recovery, re-operation, and hospital stay duration. Pancreatic fistula and leaks have been the Achillies heal of this procedure since its adoption and represents a significant impact on outcomes, mortality, and quality of life for patients.

Q3 Medical Group has dedicated itself to creating biodegradable and micro invasive solutions to help Hepatopancreatobiliary (HPB) Surgeons around the world address these unmet clinical needs. We at Q3 believe that by making small steps in procedural outcomes through the reduction or minimization of complications, it can benefit these critically ill patients in some small way and that through the additions of many small improvements there is a real opportunity to change the long-term survival rate and economic cost for those affected by this disease.

Together, collectively, with small changes that add up to larger scale changes we can make a difference. Please help us continue our fight against pancreatic cancer even if in a small way!

Eric Mangiardi
CEO, Q3 Medical Group

References

Whipple AO. Pancreaticoduodenectomy for islet carcinoma: a five-year follow-up. Ann Surg. 1945;121:847–52.

Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: A joinpoint regression analysis. World J Gastroenterol. 2022 Aug 28;28(32):4698-4715. doi: 10.3748/wjg.v28.i32.4698. PMID: 36157927; PMCID: PMC9476884.

National Guideline Alliance (UK). Pancreatic cancer in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2018 Feb. (NICE Guideline, No. 85.) 11, Management of unresectable pancreatic cancer.

Q3 MEDICAL GROUP
20 HOLLES STREET | DUBLIN 2 | IRELAND | PHONE +49 172 243 9649 | WWW.Q3MEDICAL.COM

CREATING VALUE BY HELPING PEOPLE

MADE IN GERMANY